We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-20.14%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$243M
AUM Growth
-$279M
Cap. Flow
-$206M
Cap. Flow %
-85.09%
Top 10 Hldgs %
82.71%
Holding
61
New
5
Increased
9
Reduced
8
Closed
38

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$27.5M
2
HRTX icon
Heron Therapeutics
HRTX
+$20.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.77M
4
INSM icon
Insmed
INSM
+$5.98M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$5.75M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$30.2M
2
VTRS icon
Viatris
VTRS
+$25.5M
3
EXEL icon
Exelixis
EXEL
+$25.4M
4
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$21.5M
5
TVRD
Tvardi Therapeutics
TVRD
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 57.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
51
DELISTED
Allergan plc
AGN
– –
-158,712
Closed -$30.2M
FOMX
52
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-747,308
Closed -$4.28M
ACHN
53
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,583,954
Closed -$5.83M
ARQL
54
DELISTED
Arqule Inc
ARQL
– –
-1,737,397
Closed -$9.83M
DOVA
55
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-1,026,906
Closed -$21.5M
ONCS
56
DELISTED
OncoSec Medical Incorporated
ONCS
– –
-6,313
Closed -$1.94M
SGYP
57
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-746,200
Closed -$1.27M
ECYT
58
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-654,532
Closed -$11.6M
KERX
59
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-200,000
Closed -$680K
OMED
60
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-634,715
Closed -$1.35M
IMDZ
61
DELISTED
Immune Design Corp.
IMDZ
– –
-42,304
Closed -$146K
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Nexthera Capital held 61 positions worth $243M, down 54% from $522M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Nexthera Capital withdrew a net $206M in Q4 2018, closing 38 positions and reducing 8 holdings. Its most notable exit was Allergan plc, an estimated $30.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 65% a quarter earlier.

Against the trend, Nexthera Capital opened a new position in Novartis worth $27.1M.

  • Nexthera Capital's largest Q4 2018 buy was Novartis: 352,787 shares worth $27.1M.
  • Nexthera Capital added most to Heron Therapeutics in Q4 2018, an estimated $20.1M increase.
  • Nexthera Capital's biggest Q4 2018 reduction was Exelixis, cutting an estimated $25.4M.
  • Nexthera Capital fully exited Allergan plc in Q4 2018, selling an estimated $30.2M.
  • Nexthera Capital's ten largest holdings make up 83% of its $243M portfolio in Q4 2018.
  • Nexthera Capital opened 5 new positions and closed 38 in Q4 2018.
  • Nexthera Capital's portfolio value fell 54% quarter-over-quarter to $243M.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.